It remains unclear what impact the consolidation within the drug-distribution sector may have on pricing. Pfizer partners with France’s Cytoo for its new gene therapy approach to DMD, while Gilead teams with Precision BioSciences for its goal to cure HBV.

A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.

A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.

Ranbaxy is back in the news for GMP violations at its Dewas unit in India. Based on an inspection in June, this time Germany’s drug regulator has raised the red flag, citing deficiencies in design and clean room operations, among others. For its part, Ranbaxy clarified that it had decided to discontinue making injectable cephalosporins well before the joint inspection and that all its other facilities were cleared post the inspection.